Navigation Links
Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Date:10/28/2008

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report its operating results for the third quarter and first nine months of fiscal 2008 on Wednesday, November 5.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m. Eastern Standard Time), Wednesday, November 5, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference can be accessed by calling (719) 325-4761, passcode 8632414. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at http://www.volcanocorp.com.

A replay of the conference call will be available through Wednesday, November 12, at (719) 457-0820, passcode 8632414, and via the company's website.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any mod
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an investigational ... by Shionogi & Co., Ltd., met its primary ... (COMPOSE I) for the treatment of opioid-induced constipation ... receiving opioid therapy. Study results showed that naldemedine ... improved the frequency of spontaneous bowel movement (SBM) ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today announced ... Molecular Intelligence®, the company,s panomic, comprehensive tumor profiling ... several rare and difficult to treat gynecological cancers ... potential to improve patient outcomes. These studies were ... Society of Gynecologic Oncology (SGO) 2015 Annual Meeting ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 As a ... often required by our pharmaceutical manufacturing clients, Whitehouse Laboratories ... sponsorship of the Berkenstock Race Team for the 2015 ... not only speed, but a strong sense of precision ... that lead to success in the quality control testing ...
(Date:3/27/2015)... März 2015  Peter Walter wurde als ... für seine bahnbrechende Arbeit ausgewählt, die sich ... werden, sowie für die Entschlüsselung der Komponenten ... Stress nutzen, der mit der Ansammlung von ... für Biochemie an der University of California, ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... , , , , , , , ... Protocol No. 4308 915.522 03/2002 , , , , , ... , Microorganism , Mycobacterium smegmatis LR222, ... Bacteria, gram positive, , , ...
... , , , , , , , , ... Protocol No. 4308 915.521 02/2002 , , , , , ... , Microorganism , Mycobacterium intracellulare 1403, ... Bacteria, gram positive, , , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.520 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
Cached Biology Technology:Mycobacterium smegmatis 2Mycobacterium intracellulare 2Listeria monocytogenes 2
(Date:3/11/2015)... , March 11, 2015   The Sync ... platform to scientifically measure and harness music to ... real-time biometrics and objective measurements of physiology, enabling ... at scale in large populations. It is designed ... and clinicians perform rigorous studies and accelerate the ...
(Date:3/10/2015)... Transforming How We Look at ... in Human Space Flight" by Michael A. ... Ph.D. was recently featured by Springer Science Media, highlighting the ... Specifically, "Personalized Medicine in Human Space Flight" was ... 2013 and 2014 from Springer in the journal ...
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. ... or the "Company"), a biometric authentication company focused ... company,s Wocket™ smart wallet has been named the ... Rethink Modern. Rethink Modern ( http://www.rethinkmodern.com/ ... innovative items for your home and lifestyle that have a ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... The first State of the Carbon Cycle Report for North ... Science Program, finds the continents carbon budget increasingly overwhelmed by ... tons of carbon into the atmosphere each year, mostly as ... may remove up to half this amount, but these current ...
... In the December 1st issue of G&D, Dr. Hailing ... of a new class of small RNAs in Arabidopsis. ... dubbed long short interfering RNAs (lsiRNAs), and are induced ... liRNAs share some hallmark features with other, previously identified ...
... Researchers from Kaiser Permanente and the California Department of ... nationwide, today will begin enrolling families in the largest ... that may cause autism and other developmental disabilities. ... Early Development, will involve 2,700 children and their parents ...
Cached Biology News:First-ever 'State of the Carbon Cycle Report' finds troubling imbalance 2Largest study to investigate risk factors of autism to begin enrolling families 2
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: